Purification of human IgG4 subclass with allergen-specific blocking activity

Lambin, P.; Bouzoumou, A.; Murrieta, Maricela Urías; Debbia, Martine; Rouger, Ph.; Leynadier, F.; Levy, David A.

doi:10.1016/0022-1759(93)90111-j

Cited by 32 publications

(20 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This suggests a functional role of IgG4 in inhibition of IgE-FAB, which may be due to changes in their specificity and/or affinity. Another role of allergen-specific IgG4 antibodies induced by immunotherapy is their ability to block allergen-induced IgE-dependent histamine release by basophils confirming the functional blocking activity of these antibodies (Ball et al, 1999;Lambin et al, 1993).…”

Section: Discussionmentioning

confidence: 76%

The IgE-facilitated allergen binding (FAB) assay: Validation of a novel flow-cytometric based method for the detection of inhibitory antibody responses

Shamji

Wilcock

Wachholz

et al. 2006

Journal of Immunological Methods

136

129

View full text Add to dashboard Cite

The IgE-Facilitated Allergen Binding (IgE-FAB) assay represents an in vitro model of facilitated allergen presentation. Allergen-IgE complexes are incubated with an EBV-transformed B-cell line and complexes bound to CD23 on the surface of cells are detected by flow cytometry. Addition of serum from patients who have received allergen-specific immunotherapy has been shown previously to inhibit allergen-IgE complex binding to CD23 on B cells.In this study, we describe the characterisation and analytical validation of the grass pollen-specific IgE-FAB assay according to guidelines from the International Conference on Harmonisation. We established the intra and inter -assay variability of IgE-FAB and have defined the detection limits of this assay. We have also demonstrated assay linearity and robustness. Using results from a randomised double-blind placebo controlled trial of grass pollen immunotherapy (n=33), we have defined the clinical sensitivity and specificity of the IgE-FAB assay using ROC curve analysis.In conclusion, the IgE-FAB assay is reproducible, robust, sensitive and specific method suitable as a tool for monitoring inhibitory antibody function from patients receiving allergen immunotherapy.

show abstract

Section: Discussionmentioning

confidence: 76%

The IgE-facilitated allergen binding (FAB) assay: Validation of a novel flow-cytometric based method for the detection of inhibitory antibody responses

Shamji

Wilcock

Wachholz

et al. 2006

Journal of Immunological Methods

136

129

View full text Add to dashboard Cite

show abstract

“…The kinetics of specific IgG production against L3 was determined in human anisakiasis allergy cases by Daschner et al (2002). Although somewhat controversial, specific IgG 4 production has been evaluated by investigators of allergic diseases, as IgG 4 binds to epitopes recognized by specific IgE, and is regarded as an indicator of allergic disease states (Hagan et al, 1991;Lambin et al, 1993;Atmadja et al, 1995;Garraud et al, 1995). In patients allergic to L3, the IgG specific for L4-ESP, once produced, was maintained at a high level for 6 mo.…”

Section: Specific Immunoglobulin G Productionmentioning

confidence: 99%

Immune reactions and allergy in experimental anisakiasis

Cho

Lee

2006

Korean J Parasitol

View full text Add to dashboard Cite

Abstract:The third-stage larvae (L3) of the parasitic nematode, Anisakis simplex, have been implicated in the induction of hyperimmune allergic reactions in orally infected humans. In this work, we have conducted a review of an investigation into immune reactions occurring in animals experimentally infected with A. simplex L3. The patterns of serum antibody productions in the experimental animals against excretory-secretory products (ESP) of A. simplex L3 contributed to our current knowledge regarding specific humoral immune reactions in humans. In our review, we were able to determine that L3 infection of experimental animals may constitute a good model system for further exploration of immune mechanisms and allergy in anisakiasis of humans. worldwide (Mattiucci et al., 1997;Shih, 2004;Ugland et al., 2004). Many epidemics have been reported in Japan and Spain (Chai et al., 2005). Increasing reports of L3 infection in fish have been documented in South Korea, in which the consumption of raw marine fish is also popular (Chai et al., 1992;Im et al., 1995;Song et al., 1995Song et al., , 1999. Easy access to endoscopes and enhanced awareness of anisakiasis among clinicians has resulted in better reporting of morbidity resultant from L3 infection. L3 infection induces the production of specific antibodies and cytokines (Kennedy et al., 1988;Daschner et al., 2001;Nieuwenhuizen et al., 2006). Antibodies can be detected 2 weeks after infection, consistent with the time courses associated with other microorganisms. Analyses of specific antibody levels are generally irrelevant to the differential diagnosis of an acute state in cases of L3 infection, because the profound pain associated with L3 penetration begins only a few hours after the consumption of infected raw fish. However, antibody level measurements are helpful both in the differentiation of tumors from the granulomas formed by infiltrating L3 and in investigations of allergic diseases (Gutierrez and Cuellar, 2002;Kim et al., 2006).The production of IgE tends to increase during parasite infections, but the ultimate effects of IgE vary considerably, depending on the host-parasite relationships. Hyperimmune allergic reactions have been closely associated with IgE production. The infection of a parasite into its normal host tends to reduce the development of allergic responses, despite the associated upshift in IgE production (van den Biggelaar et al., 2000;Yazdanbakhsh et al., 2002). By contrast, the infection of T. canis in humans, an abnormal host, induces increased allergic reactions (Sharp and Olson, 1962;Sharghi et al., 2001). A. simplex L3 has also been shown to induce allergic diseases at a high rate, principally due to the fact that humans are not a regular host of this parasite (Audicana et al., 2002;Klimpel et al., 2004).Through investigations of allergic responses to L3 for a period of more than 10 years, several shared features have been identified, which indicate that immune reactions to L3 infection evidence similar patterns in humans and experimental...

show abstract

“…23], Recent reports from the field of parasitology, however, clearly suggested that IgG4 antibodies can indeed act as blocking antibodies, both in vivo and in vitro [25][26][27][28][29], Hus sain et al [29] demonstrated that IgG4 antibodies inhibited histamine release from human basophils induced by filarial antigen. An inhibitory effect of IgG antibodies on basophil histamine release induced by inhalant allergens was report ed by some investigators [30][31][32][33][34][35][36][37]. In most of these studies, allergen and blocking antibodies were allowed to preincu bate prior to addition to the basophils.…”

Section: Introductionmentioning

confidence: 99%

Rabbit IgG Directed to a Synthetic C-Terminal Peptide of the Major Grass Pollen Allergen <i>Lol p</i> I Inhibits Human Basophil Histamine Release Induced by Natural <i>Lol p</i> I

Ree

Aalberse²

1995

Int Arch Allergy Immunol

View full text Add to dashboard Cite

The potential role of allergen-specific IgG antibodies as ‘blocking’ antibodies in allergen-induced human basophil histamine release was investigated. This was studied in a model with the major grass pollen allergen Lol p I and polyclonal rabbit antisera directed against this allergen and against a synthetic peptide of its C terminus. When allergen and antibodies were allowed to preincubate, Lol p I induced histamine release was inhibited up to 85% by the antiserum against Lol p I. By omitting preincubation, and thereby more closely mimicking an in vivo situation, up to 55% inhibition was realized. This indicates that allergen-specific IgG can act as ‘blocking’ antibody without preincubation. Immunization of rabbits with a synthetic C-terminal peptide of Lol p I resulted in antibodies reactive with natural Lol p I. Despite their 100-fold lower avidity for Lol p I (as compared with antinatural Lol p I), these antibodies had the capacity to inhibit Lol p I induced histamine release for > 90% (up to 50% without preincubation). This indicates that it is possible to block histamine release induced by a major allergen with low-avidity IgG antibodies directed against a minor proportion of the allergen (25 amino acids). IgE antibodies from the donors studied were unreactive with this synthetic peptide, indicating that for blocking activity identical epitope specificity of IgE and IgG is not essential. This opens interesting perspectives for application of synthetic peptides in immunotherapy, distinct from their effects on T cell reactivity.

show abstract

Purification of human IgG4 subclass with allergen-specific blocking activity

Cited by 32 publications

References 19 publications

The IgE-facilitated allergen binding (FAB) assay: Validation of a novel flow-cytometric based method for the detection of inhibitory antibody responses

The IgE-facilitated allergen binding (FAB) assay: Validation of a novel flow-cytometric based method for the detection of inhibitory antibody responses

Immune reactions and allergy in experimental anisakiasis

Rabbit IgG Directed to a Synthetic C-Terminal Peptide of the Major Grass Pollen Allergen <i>Lol p</i> I Inhibits Human Basophil Histamine Release Induced by Natural <i>Lol p</i> I

Contact Info

Product

Resources

About